Clinical Trial Update: Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating Sac-TMT in combination with toripalimab as first-line therapy for PD-L1 positive advanced/metastatic triple-negative breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Sac-TMT
• Toripalimab (Toripalimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: TNBC - Triple-Negative Breast Cancer, PD-L1 Positive | Phase 2 | Status: NOT_YET_RECRUITING